Selected research
Industry Research
Anti-VEGF Therapy for Cancer Industry Research Report 2026
Market perspective
The global Anti-VEGF Therapy for Cancer market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Anti-VEGF Therapy for Cancer market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Anti-VEGF Therapy for Cancer market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Anti-VEGF Therapy for Cancer market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Anti-VEGF Therapy for Cancer include Chia Tai Tianqing, Jiangsu Hengrui Pharmaceuticals, Sanofi, Roche, Pfizer, Novartis, Janssen Biotech, Exelixis and Eli Lilly, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Anti-VEGF Therapy for Cancer market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Anti-VEGF Therapy for Cancer.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Anti-VEGF Therapy for Cancer Market by Company
Chia Tai Tianqing
Jiangsu Hengrui Pharmaceuticals
Sanofi
Roche
Pfizer
Novartis
Janssen Biotech
Exelixis
Eli Lilly
Eisai
Boehringer Ingelheim
Bayer
AstraZeneca
Anti-VEGF Therapy for Cancer Segment by Type
VEGF Inhibitors
VEGFR Inhibitors
Anti-VEGF Therapy for Cancer Segment by Application
Non-small Cell Lung Cancer
Cervical Cancer
Colorectal Cancer
Renal Cell Carcinoma
Medullary Thyroid Cancer
Other
Anti-VEGF Therapy for Cancer Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-VEGF Therapy for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-VEGF Therapy for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-VEGF Therapy for Cancer.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Anti-VEGF Therapy for Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- VEGF Inhibitors
- VEGFR Inhibitors
Applications
- Non-small Cell Lung Cancer
- Cervical Cancer
- Colorectal Cancer
- Renal Cell Carcinoma
- Medullary Thyroid Cancer
- Other
Companies covered
- Chia Tai Tianqing
- Jiangsu Hengrui Pharmaceuticals
- Sanofi
- Roche
- Pfizer
- Novartis
- Janssen Biotech
- Exelixis
- Eli Lilly
- Eisai
- Boehringer Ingelheim
- Bayer
- AstraZeneca
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Anti-VEGF Therapy for Cancer by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 VEGF Inhibitors
- 2.2.3 VEGFR Inhibitors
- 2.3 Anti-VEGF Therapy for Cancer by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Non-small Cell Lung Cancer
- 2.3.3 Cervical Cancer
- 2.3.4 Colorectal Cancer
- 2.3.5 Renal Cell Carcinoma
- 2.3.6 Medullary Thyroid Cancer
- 2.3.7 Other
- 2.4 Assumptions and Limitations
3 Anti-VEGF Therapy for Cancer Breakdown Data by Type
- 3.1 Global Anti-VEGF Therapy for Cancer Historic Market Size by Type (2021-2026)
- 3.2 Global Anti-VEGF Therapy for Cancer Forecasted Market Size by Type (2027-2032)
4 Anti-VEGF Therapy for Cancer Breakdown Data by Application
- 4.1 Global Anti-VEGF Therapy for Cancer Historic Market Size by Application (2021-2026)
- 4.2 Global Anti-VEGF Therapy for Cancer Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Anti-VEGF Therapy for Cancer Market Perspective (2021-2032)
- 5.2 Global Anti-VEGF Therapy for Cancer Growth Trends by Region
- 5.2.1 Global Anti-VEGF Therapy for Cancer Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Anti-VEGF Therapy for Cancer Historic Market Size by Region (2021-2026)
- 5.2.3 Anti-VEGF Therapy for Cancer Forecasted Market Size by Region (2027-2032)
- 5.3 Anti-VEGF Therapy for Cancer Market Dynamics
- 5.3.1 Anti-VEGF Therapy for Cancer Industry Trends
- 5.3.2 Anti-VEGF Therapy for Cancer Market Drivers
- 5.3.3 Anti-VEGF Therapy for Cancer Market Challenges
- 5.3.4 Anti-VEGF Therapy for Cancer Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Anti-VEGF Therapy for Cancer Players by Revenue
- 6.1.1 Global Top Anti-VEGF Therapy for Cancer Players by Revenue (2021-2026)
- 6.1.2 Global Anti-VEGF Therapy for Cancer Revenue Market Share by Players (2021-2026)
- 6.2 Global Anti-VEGF Therapy for Cancer Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Anti-VEGF Therapy for Cancer Head Office and Area Served
- 6.4 Global Anti-VEGF Therapy for Cancer Players, Product Type & Application
- 6.5 Global Anti-VEGF Therapy for Cancer Manufacturers Established Date
- 6.6 Global Anti-VEGF Therapy for Cancer Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Anti-VEGF Therapy for Cancer Market Size (2021-2032)
- 7.2 North America Anti-VEGF Therapy for Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Anti-VEGF Therapy for Cancer Market Size by Country (2021-2026)
- 7.4 North America Anti-VEGF Therapy for Cancer Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Anti-VEGF Therapy for Cancer Market Size (2021-2032)
- 8.2 Europe Anti-VEGF Therapy for Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Anti-VEGF Therapy for Cancer Market Size by Country (2021-2026)
- 8.4 Europe Anti-VEGF Therapy for Cancer Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Anti-VEGF Therapy for Cancer Market Size (2021-2032)
- 9.2 Asia-Pacific Anti-VEGF Therapy for Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Anti-VEGF Therapy for Cancer Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Anti-VEGF Therapy for Cancer Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Anti-VEGF Therapy for Cancer Market Size (2021-2032)
- 10.2 South America Anti-VEGF Therapy for Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Anti-VEGF Therapy for Cancer Market Size by Country (2021-2026)
- 10.4 South America Anti-VEGF Therapy for Cancer Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Anti-VEGF Therapy for Cancer Market Size (2021-2032)
- 11.2 Middle East & Africa Anti-VEGF Therapy for Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Chia Tai Tianqing
- 12.1.1 Chia Tai Tianqing Company Information
- 12.1.2 Chia Tai Tianqing Business Overview
- 12.1.3 Chia Tai Tianqing Revenue in Anti-VEGF Therapy for Cancer Business (2021-2026)
- 12.1.4 Chia Tai Tianqing Anti-VEGF Therapy for Cancer Product Portfolio
- 12.1.5 Chia Tai Tianqing Recent Developments
- 12.2 Jiangsu Hengrui Pharmaceuticals
- 12.2.1 Jiangsu Hengrui Pharmaceuticals Company Information
- 12.2.2 Jiangsu Hengrui Pharmaceuticals Business Overview
- 12.2.3 Jiangsu Hengrui Pharmaceuticals Revenue in Anti-VEGF Therapy for Cancer Business (2021-2026)
- 12.2.4 Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Product Portfolio
- 12.2.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
- 12.3 Sanofi
- 12.3.1 Sanofi Company Information
- 12.3.2 Sanofi Business Overview
- 12.3.3 Sanofi Revenue in Anti-VEGF Therapy for Cancer Business (2021-2026)
- 12.3.4 Sanofi Anti-VEGF Therapy for Cancer Product Portfolio
- 12.3.5 Sanofi Recent Developments
- 12.4 Roche
- 12.4.1 Roche Company Information
- 12.4.2 Roche Business Overview
- 12.4.3 Roche Revenue in Anti-VEGF Therapy for Cancer Business (2021-2026)
- 12.4.4 Roche Anti-VEGF Therapy for Cancer Product Portfolio
- 12.4.5 Roche Recent Developments
- 12.5 Pfizer
- 12.5.1 Pfizer Company Information
- 12.5.2 Pfizer Business Overview
- 12.5.3 Pfizer Revenue in Anti-VEGF Therapy for Cancer Business (2021-2026)
- 12.5.4 Pfizer Anti-VEGF Therapy for Cancer Product Portfolio
- 12.5.5 Pfizer Recent Developments
- 12.6 Novartis
- 12.6.1 Novartis Company Information
- 12.6.2 Novartis Business Overview
- 12.6.3 Novartis Revenue in Anti-VEGF Therapy for Cancer Business (2021-2026)
- 12.6.4 Novartis Anti-VEGF Therapy for Cancer Product Portfolio
- 12.6.5 Novartis Recent Developments
- 12.7 Janssen Biotech
- 12.7.1 Janssen Biotech Company Information
- 12.7.2 Janssen Biotech Business Overview
- 12.7.3 Janssen Biotech Revenue in Anti-VEGF Therapy for Cancer Business (2021-2026)
- 12.7.4 Janssen Biotech Anti-VEGF Therapy for Cancer Product Portfolio
- 12.7.5 Janssen Biotech Recent Developments
- 12.8 Exelixis
- 12.8.1 Exelixis Company Information
- 12.8.2 Exelixis Business Overview
- 12.8.3 Exelixis Revenue in Anti-VEGF Therapy for Cancer Business (2021-2026)
- 12.8.4 Exelixis Anti-VEGF Therapy for Cancer Product Portfolio
- 12.8.5 Exelixis Recent Developments
- 12.9 Eli Lilly
- 12.9.1 Eli Lilly Company Information
- 12.9.2 Eli Lilly Business Overview
- 12.9.3 Eli Lilly Revenue in Anti-VEGF Therapy for Cancer Business (2021-2026)
- 12.9.4 Eli Lilly Anti-VEGF Therapy for Cancer Product Portfolio
- 12.9.5 Eli Lilly Recent Developments
- 12.10 Eisai
- 12.10.1 Eisai Company Information
- 12.10.2 Eisai Business Overview
- 12.10.3 Eisai Revenue in Anti-VEGF Therapy for Cancer Business (2021-2026)
- 12.10.4 Eisai Anti-VEGF Therapy for Cancer Product Portfolio
- 12.10.5 Eisai Recent Developments
- 12.11 Boehringer Ingelheim
- 12.11.1 Boehringer Ingelheim Company Information
- 12.11.2 Boehringer Ingelheim Business Overview
- 12.11.3 Boehringer Ingelheim Revenue in Anti-VEGF Therapy for Cancer Business (2021-2026)
- 12.11.4 Boehringer Ingelheim Anti-VEGF Therapy for Cancer Product Portfolio
- 12.11.5 Boehringer Ingelheim Recent Developments
- 12.12 Bayer
- 12.12.1 Bayer Company Information
- 12.12.2 Bayer Business Overview
- 12.12.3 Bayer Revenue in Anti-VEGF Therapy for Cancer Business (2021-2026)
- 12.12.4 Bayer Anti-VEGF Therapy for Cancer Product Portfolio
- 12.12.5 Bayer Recent Developments
- 12.13 AstraZeneca
- 12.13.1 AstraZeneca Company Information
- 12.13.2 AstraZeneca Business Overview
- 12.13.3 AstraZeneca Revenue in Anti-VEGF Therapy for Cancer Business (2021-2026)
- 12.13.4 AstraZeneca Anti-VEGF Therapy for Cancer Product Portfolio
- 12.13.5 AstraZeneca Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst